Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lilly wins Erbitux label expansion for colorectal cancer indication

By Brian Buntz | September 28, 2021

Eli LillyFDA has approved a new indication for Lilly‘s (NYSE:LLY) Erbitux (cetuximab injection) in combination with Pfizer’s Braftovi (encorafenib) to treat adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation confirmed with an FDA-approved test.

The indication covers previously-treated patients.

Erbitux is currently the only FDA-approved antibody that targets the epidermal growth factor receptor (EGFR). Merck (NYSE:MRK) was also involved in developing the drug.

The recent label expansion is based on data from Pfizer’s Phase 3 BEACON CRC study, which focused on patients with metastatic colorectal cancer with a BRAF V600E mutation.

ErbituxThe latest approval gives Erbitux a total of seven indications covering various colorectal and head-and-neck cancers.

“The BEACON study showed that the combination of ERBITUX and encorafenib significantly improved overall survival in patients with metastatic colorectal cancer with a BRAF V600E mutation — a subtype that typically has worse outcomes compared to those without the mutation,” said Dr. David Hyman, chief medical officer, oncology at Lilly, in a statement.

Volunteers in the trial who received cetuximab and encorafenib had a median overall survival of 8.4 months compared to 5.4 months for control-arm participants.


Filed Under: Oncology
Tagged With: BRAF V600E, Braftovi, cancer, cetuximab, EGFR, epidermal growth factor receptor, Erbitux, Lilly, Merck
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Merck in the Drug Discovery & Development Pharma 50
Merck halts Phase 3 Lynparza for futility

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50